Publication | Closed Access

An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia*

AntibioticsHealthcare-associated InfectionIv/po Co-amoxiclavRespiratory InfectionAntimicrobial PharmacokineticsInfection ControlEconomic EvaluationMedicineClinical MicrobiologyAntimicrobial Resistance